Zeghoud F, Jardel A, Garabedian M, Salvatore R, Moulias R
C.N.R.S. URA 583, Université Paris V, Hôpital Necker, Paris.
Rev Rhum Mal Osteoartic. 1990 Nov;57(11):809-13.
A clinical trial carried out during the autumn/winter season in 46 institutionalized elderly subjects (35 women, 11 men) (group mean age = 83 +/- 2 years) revealed a severe deficiency in vitamin D in these subjects (25-hydroxyvitamin D level less than or equal to 3 ng/ml). After oral administration of 100,000 IU of vitamin D3, an increase in 25-hydroxyvitamin D levels above the 10 ng/ml threshold was observed and maintained for three months. A second dose, administered after 3 months, made it possible to sustain this level. No sign of toxicity was detected, notably no trace of hypercalcemia. In contrast, no change in the deficit (25-hydroxyvitamin D level less than or equal to 3 ng/ml) was seen in the placebo population. Three-monthly administration of the moderate dosage of 100,000 IU of vitamin D3 all year round would offer a simple, effective and risk-free system to counteract vitamin D deficiency in the elderly and of preventing the risk of osteomalacia, thus reducing the incidence of fractures.
一项在秋冬季节针对46名机构养老的老年人（35名女性，11名男性）（组平均年龄 = 83 ± 2岁）开展的临床试验显示，这些受试者存在严重的维生素D缺乏（25-羟维生素D水平小于或等于3 ng/ml）。口服100,000 IU维生素D3后，观察到25-羟维生素D水平升高至10 ng/ml阈值以上，并维持了三个月。3个月后给予第二剂，使得该水平得以维持。未检测到毒性迹象，尤其是未发现高钙血症痕迹。相比之下，安慰剂组人群的缺乏情况（25-羟维生素D水平小于或等于3 ng/ml）没有变化。全年每三个月给予100,000 IU的中等剂量维生素D3，将提供一个简单、有效且无风险的系统，以对抗老年人的维生素D缺乏并预防骨软化风险，从而降低骨折发生率。
